A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have ...
New Phase 3 data show fenebrutinib reduced markers of chronic brain inflammation in both relapsing forms of MS and primary ...
The Phase 1 trial evaluated patients whose disabilities continued to worsen despite receiving other treatments.
A French Delphi study found that MRI evidence of high activity most consistently led neurologists to recommend early ...
A study found generic versions of certain MS treatments were linked to more variable disease biomarker profiles than ...
Add Yahoo as a preferred source to see more of our stories on Google. BUFFALO, N.Y. (WIVB) — More than a thousand people gathered at Terminal B at the Outer Harbor with one goal in mind Saturday ...
HOUSTON and WALTHAM, Mass., April 17, 2025 /PRNewswire/ -- Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, today announced a strategic partnership with the Accelerated ...
People with multiple sclerosis (MS) who are treated with rituximab have an increased risk of developing inflammatory bowel ...
Newswise — WALTHAM, Mass., July 31, 2024-- Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) announced today that it has named Stephanie Buxhoeveden, Ph.D., M.S.N., FNP-BC, MCSN, as its Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results